Jefferies Lowers Estimates on Nanosphere

The investment firm lowered revenue estimates and the share-price target for Nanosphere following the FDA's denial of the company's Plavix metabolism test.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.

Related Stories